CHD1L: a novel oncogene by Wen Cheng et al.
Cheng et al. Molecular Cancer 2013, 12:170
http://www.molecular-cancer.com/content/12/1/170REVIEW Open AccessCHD1L: a novel oncogene
Wen Cheng1*†, Yun Su2† and Feng Xu1Abstract
Comprehensive sequencing efforts have revealed the genomic landscapes of common forms of human cancer and
~ 140 driver genes have been identified, but not all of them have been extensively investigated. CHD1L
(chromodomain helicase/ATPase DNA binding protein 1-like gene) or ALC1 (amplified in liver cancer 1) is a newly
identified oncogene located at Chr1q21 and it is amplified in many solid tumors. Functional studies of CHD1L in
hepatocellular carcinoma and other tumors strongly suggested that its oncogenic role in tumorigenesis is through
unleashed cell proliferation, G1/S transition and inhibition of apoptosis. The underlying mechanisms of CHD1L
activation may disrupt the cell death program via binding the apoptotic protein Nur77 or through activation of the
AKT pathway by up-regulation of CHD1L-mediated target genes (e.g., ARHGEF9, SPOCK1 or TCTP). CHD1L is now
considered to be a novel independent biomarker for progression, prognosis and survival in several solid tumors.
The accumulated knowledge about its functions will provide a focus to search for targeted treatment in specific
subtypes of tumors.
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Cancer is a disease of genome. International efforts in
cancer genomic research have revealed that numerous
somatic mutations, genomic rearrangement and structure
variants in various type of cancer [1]. Approximately three
to six genetic events are necessary to transform a normal
cell into a cancer cell [2]. On average, two to eight somatic
driver mutations occur in a typical tumor; the remaining
are passenger mutations that confer no selective growth
advantage. Critical genetic changes (in combinatory effect)
reprogram the normal cell growth in several core signaling
pathways to change the cell fate, cell survival and genome
maintenance [1]. Driver genes are recently suggested to be
categorized into “mut-driver genes” and “epi-driver genes”.
Mut-driver genes contain a sufficient number or type
of driver gene mutations; while epi-driver genes are
expressed aberrantly in tumors but not frequently
mutated; they are altered through changes in DNA methy-
lation or chromatin modification that persist as the tumor
cell divides [1]. A collection of all causalities of malignant
transformation (also called the cancer initiatome [3]) mea-
sured with conventional molecular biological techniques* Correspondence: Dr_Chengwen@126.com
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reproduction in any medium, provided the oror whole genome sequencing technologies will help us to
find solutions to conquer cancer. Chromosomal rear-
rangements during tumorigenesis have been found to be
common genomic abnormalities including amplifications,
deletions or translocations that may result from a cata-
strophic shattering of one or more chromosomes followed
by misjoining of the scrambled fragments upon repair, and
kataegis [4].
Amplification of 1q21 is one of the most frequent gen-
etic alterations in many solid tumors, including bladder
[5], breast [6], nasopharyngeal carcinoma [7], hepatocellu-
lar carcinoma [8], esophageal tumor [9], fibrosarcoma of
bone [10], colorectal carcinoma [11]. Chromodomain heli-
case/ATPase DNA binding protein 1-like gene (CHD1L) is
a recently identified oncogene that is frequently amplified
in hepatocellular carcinoma (HCC) [12]. CHD1L exhibits
an oncogenic role during malignant transformation. Over-
expression of CHD1L protein in tumors is considered to
be a biomarker of poor prognosis and short tumor-free
survival time. In this review, we will discuss more about
the structure and function of CHD1L gene and its
underlying molecular mechanisms during tumorigenesis.
Finally, we will propose strategies for developing a CHD1L
inhibitor for potential treatment.Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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Human CHD1L gene, also known as ALC1 (amplified in
liver cancer 1), was identified by Ma et al. in 2008 [12].
This gene is located at Chr 1q21.1 (genomic coordinate:
chr 1:146,714,292-146,767,443, strand (+)). CHD1L gene
is 53,152 base pairs long and it contains 23 exons. Up-
stream of CHD1L gene is flavin containing monooxygen-
ase 5 (FMO5) gene, and downstream of CHD1L gene is
prostaglandin reductase pseudogene (LOC100130018)
and a long intergenic noncoding RNA 624 (LINC00624)
(illustrated in Figure 1). Six alternatively spliced tran-
script variants have been described for this gene (http://
www.ncbi.nlm.nih.gov/nuccore/?term=CHD1L). Interest-
ingly, transcript variant 6 is a noncoding transcript; this
is an example of coding RNAs that could serve as both
coding and noncoding molecules depending on cellular
context [13]. The corresponding proteins encoded from
transcript variants are listed in Table 1. The full-length
messenger RNA of CHD1L consists of 2,980 base pairs
(3,036 bp in recent database) with a putative open
reading frame coding an 897aa protein [12]. Protein
sequencing analysis showed that CHD1L belongs to the
SNF2-like family, containing a conserved SNF2_N do-
main, which is a helicase superfamily domain (helicase
superfamily c-terminal domain (HELICc)), and a Macro
domain [12] (Figure 1). The SNF2_N domain is composedFigure 1 Genomic information of human CHD1L gene (chromodomain
locus of CHD1L gene is located on the long arm q21 of Chromosome 1 wi
containing monooxygenase 5) and upstream of LOC10030018 (prostagland
exons (green boxes), which may be transcribed with six transcript variants.
is illustrated. CHD1L protein is comprised of two helicase domains (yellow
sequence (NLS, purple color). There are two putative phosphorylation sites
891 amino acids, respectively.of 280 amino acids, and the sequence homology between
the SNF2_N domains of CHD1L and another SNF2-like
family member, chromodomain helicase DNA binding
protein 1 (CHD1), is 45% identical. The sequence hom-
ology of the HELICc domain (containing 107aa) between
CHD1L and CHD1 is 59% identical [12]. Therefore, the
name of chromodomain-helicase-DNA-binding protein
1-like, CHD1L, was given. A total of 64 different muta-
tions have been reported in catalogue of somatic muta-
tions in cancer (COSMIC) (http://cancer.sanger.ac.uk/
cosmic/gene/analysis?ln=CHD1L#dist). These mutations
are classified into substitution mutations (nonsense, mis-
sense, synonymous), insertion frameshift mutation and
other (mutations occur at intronic regions). Among these
mutations, the substitution missense mutations account
for 56.67% as shown in the distribution chart. Since
substitution missense mutations change the amino acids
of the protein, and may affect the CHD1L functions. We
listed these mutational locations at cDNA level (Figure 2).
Recently, CHD1L mutations were detected in congenital
anomalies of the kidneys and urinary tract (CAKUT) pa-
tient [14]. How these mutations change CHD1L biological
functions in cancer cells remains to be explored. CHD1L
expression was detected in different tissues using high
density oligonucleotide microarray, in particular, it ex-
presses at higher levels in early erythroid cells, CD34 cells,helicase/ATPase DNA binding protein 1-like gene). The genomic
th 53,152 base pairs in length. It is downstream of FMO5 gene (flavin
in reductase 1 pseudo gene) and LINC00624. CHD1L contains 23
The full-length transcript (NM_004284.2) and encoded protein structure
color), a C-terminal macro domain (blue color) and nuclear localization
at the relative C-terminus of the protein: phospho-serine at 636 and
Table 1 List of CHD1L transcript variants
CHD1L mRNA RefSeq # Transcripts Protein notes
Variant 1 NM_004284.4 3,036 bp 897 aa Full length
Variant 2 NM_001256336.1 2,929 bp 803 aa 331-424 missing
Variant 3 NM_024568.2 3,008 bp 784 aa 1-113 missing
Variant 4 NM_001256337.1 2,506 bp 616 aa 44-246 missing
Variant 5 NM_001256338.1 2,424 bp 693 aa 43-246 missing
Variant 6 NR_046070.1 2,851 bp Non coding transcript
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(K562, HL60) [15]. Like other SNF2 chromatin remodel-
ing proteins, CHD1L is localized to the nucleus.
The functions of CHD1L
CHD1L is a recently identified oncogene located at
1q21, a frequently amplified region in hepatocellular
carcinoma (HCC) [12]. The biochemical functions of
CHD1L were predicted based on the protein structure
similarity with CHD1. The CHD1 family of proteins
is characterized by the presence of chromo (chroma-
tin organization modifier) domains and SNF2-related
helicase/ATPase domains. CHD1 protein is able to
bind DNA and regulate ATP-dependent nucleosomeFigure 2 The distribution of mutations in CHD1L. The pie chart shows
synonymous, insertion frame shift and others. The substitution missense m
displayed. The data is obtained from the catalogue of somatic mutations in
ln=CHD1L#dist).assembly, modification of chromatin structure and
mobilization through their conserved double chromodo-
mains and SNF2 helicase/ATPase domain [16]. Sequence
comparison showed that CHD1L contains SNF2-N domain
and a helicase superfamily domain; therefore, CHD1L has
also been hypothesized to play important roles in tran-
scriptional regulation, maintenance of chromosome integ-
rity and DNA repair. But unlike CHD1, CHD1L does not
contain a chromodomain, which can recognize methylated
histone tails. Instead, CHD1L contains a macro domain
[12], which is an adenosine 5′-dephosphate (ADP)-ribose/
polymer of ADP-ribose (PAR)-binding element [17]. Thus,
CHD1L possesses a PAR-dependent chromatin remodeling
activity and facilitates DNA repair reactions within athe percentage of mutations of substitution missense, nonsense,
utations at the cDNA strand (2694 nucleotides) of CHD1L are
cancer (COSMIC). (http://cancer.sanger.ac.uk/cosmic/gene/analysis?
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activities of CHD1L are strongly activated by the poly
(ADP-ribose) polymerase Parp1 and its substrate NAD+
via transient interaction between intact macrodomain and
chromatin-associated proteins, including histones and
Parp1 [19]. This CHD1L nucleosome remodeling activity
depends on the formation of a stable CHD1L-PARylated
PARP1-nucleosome intermediate [20].
In addition to the PAR binding, the C-terminal macro
domain (residues 600–897) of CHD1L is able to bind the
protein Nur77: a critical member of a p53-independent
apoptotic pathway. This binding subsequently inhibits the
nucleus-to-mitochondria translocation of Nur77, which is
the key step of Nur77-mediated apoptosis. Retention of
Nur77 protein in the nucleus by CHD1L results in pre-
venting release of cytochrome c from mitochondria and
blocking the initiation of apoptosis [21] (Figure 3-(II)).
Moreover, the chromatin-remodeling function of CHD1LFigure 3 The underlying mechanisms of oncogenic role of CHD1L du
overexpressed in tumors (I). The macro domain of CHD1L protein interacts
translocation and the subsequent Nur77-mediated caspases’ activation and
the promoter regions of target genes and activate gene transcription, such
such as cell survival, invasion, metastasis and genome instability (III-V).plays important role in the earliest cell divisions of mam-
malian development [22].
CHD1L appears to function as a transcription factor. A
chromatin immunoprecipitation-based cloning strategy
unveiled that CHD1L confers DNA-binding capability to
activate gene expression of direct targets that are relevant
to oncogenesis. ARHGEF9 (Rho guanine nucleotide ex-
change factor 9), which encodes a specific guanine nucleo-
tide exchange factor for the Rho small GTPase Cdc42,
was identified as a CHD1L target gene [23]. CHD1L pro-
tein also directly binds to the promoter region (nt −733
to −1,027) of TCTP (translationally controlled tumor
protein) [24] and the promoter region (nt −1662 to +34)
of SPOCK1 (sparc/osteonectin, cwcv, and kazal-like
domains proteoglycan 1) [25], subsequently activating
these target genes’ transcription. The transcriptional
regulation of these genes by CHD1L could partially
explain the mechanisms of CHD1L oncogenic role inring tumorigenesis. CHD1L is amplified at Chr1q21 region and
with Nur77 and inhibits the latter’s nuclear to mitochondrial
cell death (II). On the other hand, CHD1L protein may directly bind to
as ARHGEF9, TCTP and SPOCK1, leading to various biological effects
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Collectively, CHD1L interacts with other proteins or
regulates target gene expression to execute its biological
effects.
CHD1L and Cancer
Amplification of 1q21 region was reported in multiple
solid tumors [5-7,9-11]. In hepatocellular carcinoma
(HCC), amplification of 1q21 is the most frequent gen-
etic alteration, being detected in 58%-78% of primary
HCC cases by comparative genomic hybridization [8].
This phenotype leads cancer biologists to wonder why
this region is amplified and what genes are misregulated
in this region. In 2008, Ma et al. [12] first isolated
CHD1L as a target gene within the 1q21 amplicon using
chromosome microdissection/hybrid selection approach.
Recently, several genes including CHD1L in regions for
amplification at 1q21-24 in urothelial carcinoma were
identified by array-CGH for high-resolution zoom-in
oligonucleotide array analyses [26]. From HCC studies,
CHD1L was not only detected to be amplified via FISH,
but its mRNA and protein were also overexpressed in
the examined samples [12]. Additionally, CHD1L-trans-
fected cells possessed a strong oncogenic ability with
increased colony formation in soft agar and the tumori-
genity in nude mice. This phenotype could be effectively
suppressed by small interfering RNA against CHD1L
[12]. To further investigate the in vivo oncogenic role of
CHD1L, a transgenic mouse model that ubiquitously
expresses CHD1L was generated by Chen et al. [27].
Spontaneous tumor formation was found in 10/41
(24.4%) transgenic mice, including 4 HCCs, that were
not found in their 39 wild-type littermates. Furthermore,
overexpression of CHD1L in hepatocytes could promote
tumor susceptibility in CHD1L-transgenic mice [27].Table 2 List of the studies of Chr1q and/or CHD1L amplificati
Tumor origin Chr1q/CHD1L Technique used
Breast Chr1q ( 67%) CGH
Bladder Chr1q ( 54%) CGH
CHD1L PCR
Chr1q21-24 CGH + expression




( 56 ~78%) FISH
Chr1q21 TMA + IHC
CHD1L
CHD1L
Ovarian CHD1L TMA + IHCThe oncogenic role of CHD1L in tumorigenesis in vitro
and in vivo was also observed in colorectal carcinoma
[11]. CHD1L expression in HPV-infected immortalized
cervical cells appears to accelerate the malignant trans-
formation with NNK chemical exposure [28]. All of this
evidence strongly suggests that CHD1L functions as a
driver gene during cancer development.
The clinical significance of amplification and overex-
pression of CHD1L have been evaluated in solid tumors,
including HCC [29], ovarian carcinoma [30], colorectal
carcinoma [11], and bladder cancer [31]. All these stud-
ies demonstrated that CHD1L is a novel biomarker for
prediction of progression, prognosis and survival
(Table 2). For example, we found that CHD1L protein
expression was significantly higher in bladder cancer
than in adjacent noncancerous tissues. CHD1L overex-
pression was significantly correlated with histologic
grade and tumor stage. The Kaplan-Meier survival ana-
lysis revealed that survival time of patients with higher
CHD1L expression was significantly shorter than that
with lower CHD1L expression [31]. The role of CHD1L
in chemotherapy response of patients with HCC was
also investigated [32]. CHD1L could selectively inhibit
apoptosis induced by 5-fluorouracil (5-FU) but not
doxorubicin. The phenotype of chemo-resistance could
be reversed by short hairpin siRNAs against CHD1L
in vitro cell culture and in vivo mouse model [32]. Taken
together, CHD1L is a novel oncogene and could be used
as an indicator of poor prognosis and chemo-resistance.
The mechanisms of CHD1L-driven oncogenesis
Driver genes (mut-driver genes or epi-driver genes) confer
selective growth advantage that can be classified into 12
signaling pathways, which regulate three core cellular













Metastatic cancer with poor prognosis [30]
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cells? Functional studies showed that overexpression of
CHD1L could promote cell proliferation, accelerate G1/S
phase transition and inhibit apoptosis [11,12]. In a trans-
genic mouse model, CHD1L could facilitate DNA syn-
thesis and G1/S transition through the up-regulation of
Cyclins (A, D1 and E), CDK2, 4, and down-regulation of
Rb, p27 (Kip1), and p53 [27].
CHD1L-mediated transcriptional activation of target
genes seems to play crucial roles during cancer develop-
ment. Functional studies in vitro and in vivo showed that
CHD1L contributed to tumor cell migration, invasion,
and metastasis by increasing cell motility and inducing
filopodia formation and epithelial-mesenchymal transi-
tion (EMT) via ARHGEF9-mediated Cdc42 activation.
Therefore, CHD1L-ARHGEF9-Cdc42-EMT might be a
novel pathway involved in HCC progression and metas-
tasis [23] (Figure 3-(IV)).
As mentioned before, TCTP and SPOCK1 are direct
transcriptional targets of CHD1L. CHD1L-mediated
overexpression of TCTP was detected in 40.7% of
human HCC samples. Clinically, overexpression of
TCTP was significantly associated with the advanced
tumor stage and overall short survival time of HCC
patients. In multivariate analyses, TCTP was determined
to be an independent marker associated with poor prog-
nostic outcomes. Functional studies in vitro and in vivo
demonstrated that TCTP has tumorigenic abilities, and
overexpression of TCTP induced by CHD1L contributed
to the mitotic defects in tumor cells. The mechanism of
mitotic defect from overexpression of TCTP is that
TCTP promotes the ubiquitin-proteasome degradation
of Cdc25C during mitotic progression, which caused the
failure in the dephosphorylation of Cdk1 on Tyr15 and
decreased Cdk1 activity. As a consequence, the sudden
drop of Cdk1 activity in mitosis induced a faster mitotic
exit and chromosome missegregation, which led to
chromosomal instability. Depletion of TCTP can prevent
the mitotic defect. Collectively, CHD1L-TCTP-Cdc25C-
Cdk1 is a novel molecular pathway, which causes the
malignant transformation of hepatocytes with the
phenotypes of accelerated mitotic progression and the
production of aneuploidy [24] (Figure 3-(V)).
CHD1L-mediated upregulation of SPOCK1 can pre-
vent apoptosis of HCC cells through activating Akt
signaling pathway, blocking release of cytochrome c and
activating caspase-9 and caspase-3. These effects were
abolished with an Akt inhibitor. Additionally, HCC cells
with overexpression of SPOCK1 have higher levels of
matrix metallopeptidase 9, these cells were more inva-
sive, and developed more metastatic nodules in immu-
nodeficient mice than HCC cells with lower SPOCK
expression [25] (Figure 3-(III)). Taken together, CHD1L
activates cell survival pathways and inhibits programmedcell death signaling, resulting in cell fate change
(malignant transformation) through complex mechanisms.Targeting CHD1L for potential treatment
Identification of cancer driver genes can lead to better
diagnosis and successful targeted therapies. We are
proposing here to develop small molecules to target
degradation of oncogenic CHD1L gene and its encoded
products. Hopefully this strategy could disrupt the
putative pathways or counterparts, in turn, restore the
normal cellular functions. Compelling experimental data
in vitro and in vivo showed that knockdown of CHD1L
gene expression using specific RNA interfering mole-
cules could change the cancer cell behaviors through
inducing apoptosis (Figure 3-(I)). Silencing CHD1L
expression in HCC by the corresponding shRNA has a
great therapeutic potential in HCC treatment, especially
to increase the chemo-sensitivity combined with 5-FU
chemotherapy [32]. siRNA-based therapy is emerging as
a promising approach for a treatment. Several siRNA-
mediated therapies are in clinical trial [33]. We propose
that CHD1L-shRNA should be investigated for its utility
as a targeted therapy based on the current preclinical
evidence. Alternatively, because CHD1L contains a
macrodomain, interacting with multiple counterparts
(e.g., PARP1 and Nur77) to execute its biological effects;
therefore, targeting macro domains might enhance the
effectiveness of radiotherapy and chemotherapy [34]. The
ideas could be: 1) utilizing PARP1 inhibitor; 2) designing
small molecules to prevent Nur77 binding, resulting in
increasing apoptotic pathways (Figure 3-(II)); 3) inhibiting
target genes of CHD1L to inactivate downstream path-
ways (Figure 3-(III-V)). Ideally, combining all these strat-
egies may have additive or synergistic effects. One might
utilize the computer-aided drug design with high-
throughput screening of known small molecule library
(repositioning drug discovery) technology to achieve this
goal in an efficient and inexpensive manner.Conclusion
Since CHD1L gene was isolated from the amplicon of
Chr1q21 in tumors, the functional studies point to the
oncogenic role of CHD1L in solid tumors, particularly in
hepatocellular carcinoma. The unique protein structure
of CHD1L with macro domain interacting with other
protein partners executes a variety of biological func-
tions such as DNA damage repair and anti-apoptosis.
Moreover, CHD1L-mediated gene activation may confer
regulatory function in malignant transformation. Better
understanding of CHD1L genomic functions will likely
pave the way for novel therapeutic strategies (siRNA,
small molecules) to modulate critical signaling pathways
in cancer.
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